On a global scale, cancer and cardiovascular diseases encompass more than 65% of death causes. Cardio-oncology is a novel field that aims to reduce mortality and cardiovascular morbidity in cancer patients, mainly focusing on prevention, diagnosis, follow-up, and treatment of cardiovascular toxicity secondary to chemotherapy.

Prevention of cardiotoxicity can only be obtained by the early detection of chemotherapy-induced cardiovascular disorders, and this implies refined new biomarkers and imaging techniques, but also knowing “when” to intervene with protective drugs.

This Special Issue aims to collate research articles with a focus on biomarkers and imagistic techniques for the early diagnosis and follow-up of cardiovascular toxicity induced by cancer therapy. The submission of review articles which describe the current state of the art, or systematic reviews is encouraged, but original research articles are especially welcomed.

Potential topics include but are not limited to the following:

• Classical and novel biomarkers (conventional and high-sensitive troponin I and T, natriuretic peptides, myeloperoxidase, microRNA, peripheral blood mononuclear cell gene expression profile, ST-2, galactin-3, high-sensitive CRP, GDF-15) for risk stratification and early the detection of cardiac toxicity (ischemia, cardiomyopathy, heart failure etc.) in population on cancer therapy
• Biomarkers of vascular disease (thromboembolic disease, peripheral artery disease, pulmonary hypertension) and hypertension related to chemotherapy
• Potential early diagnosis techniques (ECG, cardiac ultrasound, 2D and 3D strain echocardiography, global strain echocardiography, cardiac MRI) as surrogates to better emphasize a patient at risk of cancer therapy induced-cardiac toxicity
• Immunological mechanism of cardiovascular toxicity induced by novel cancer therapy